Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
Compassionate use access to molibresib/GSK525762 for eligible participant with NUT Midline Carcinoma; indication is a seriously debilitating or life-threatening disease.
Solid Tumours
DRUG: molibresib
Investigational Product GSK525762 is an orally bioavailable small molecule that is a potent inhibitor of the binding of BET proteins to acetylated histones. Binding of GSK525762 induces squamous differentiation and inhibits proliferation of patient-derived NMC cell lines both in culture and in murine xenografts.

Compassionate use access to molibresib is restricted to patients with confirmed diagnosis of NUT Midline Carcinoma.